News
March 18, 2019
Study Evaluates Two Drug Therapies on Children with Lupus Nephritis
Today, lupus treatment in children is based on research conducted on adults. A new study analyzed treatment response, damage accrual, and disease activity in 51 children (16 years old or younger) with juvenile-onset lupus nephritis. The study analyzed data collected from juveniles who were treated with mycophenolate mofetil (a drug that prevents organ rejection) or cyclophosphamide (a drug used to treat nephrotic syndrome). While there were no statistically significant differences identified between the two therapies, researchers concluded that further study should include children with ethnically diverse backgrounds. Ultimately, more research in children with lupus nephritis is needed. Learn about lupus and children.
See More:
The latest from Inside Lupus Research
News
UPDATE: Gazyva® Shows Superiority Over Standard Therapy for People with Active Lupus Nephritis
News
UPDATE: Investigational CAR-T Cell Therapy ADI-001 Receives FDA Fast Track Designation for Refractory Systemic Lupus Erythematosus with Extrarenal Involvement
News
New Study Finds Racial and Gender-Specific Approaches May Boost Black Participation in Lupus Clinical Trials
News
Centers for Medicare and Medicaid Services Announces Medicare Pricing for Two Progentec Diagnostics Tests Used in Systemic Lupus Erythematosus Treatment